Pfizer raises full-year 2025 EPS guidance to $3–$3.15 amid Metsera acquisition progress and R&D pipeline expansion

Q3 2025 Management View CEO Albert Bourla highlighted that "the past few months have been pivotal for Pfizer" with key developments including an agreement with the U.S. government, the proposed ...